Search ARM

Q3 2019 Data Report


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape

959+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total Q3 2019 Global Financings

Total Global Financing

$2.6 Billion

 7%

Decrease from Q3 2018

 32%

Decrease year-over-year
$7.4B Raised YTD 2019

Gene & Gene-modified
Cell Therapy

$1.3 Billion

 38%

Decrease from Q3 2018

 30%

Decrease year-over-year
$5.6B raised YTD 2018

Cell Therapy

$1.6 Billion

 13%

Decrease from Q3 2018

 48%

Decrease year-over-year
$3.3B raised YTD 2019

Tissue Engineering

$40 Million

 327%

Increase from Q3 2018

 86%

Decrease year-over-year
$114M raised YTD 2019

Total Global Financings by Type, by Year

1052

Clinical trials underway
worldwide by the end of Q3 2018

PH. 1

363

PH. 2

594

PH. 3

95

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q3 2019

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q3 2019

Report Infographics